Jeffrey A. Silverman
- Oncology top 1%
- Drug Transport and Resistance Mechanisms 31
- Pharmacology top 0.5%
- Pharmaceutical Science top 1%
-
- Pharmacological Effects and Toxicity Studies 12
- Childhood Cancer Survivors' Quality of Life 6
- Biomaterials top 2%
-
- Acute Lymphoblastic Leukemia research 15
-
- Cancer therapeutics and mechanisms 10
- DNA Repair Mechanisms 5
-
- Amino Acid Enzymes and Metabolism 9
-
- Chronic Lymphocytic Leukemia Research 6
- Co-authors
- Jay DintamanSteven R. DeitcherVincent J. WacherLeslie Z. BenetSnorri S. ThorgeirssonYuanchao ZhangTimothy W. GantDieter Schrenk
- Journals
- Nucleic Acids Research (2 papers)Journal of Clinical Oncology (3 papers)SHILAP Revista de lepidopterología (1 paper)
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Jeffrey A. Silverman
90 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 122
- Oncology 2.0k
- Pharmacology 619
- Pharmaceutical Science 335
- Pediatrics, Perinatology and Child Health 856
- Biomaterials 450
Countries citing papers authored by Jeffrey A. Silverman
This map shows the geographic impact of Jeffrey A. Silverman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey A. Silverman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey A. Silverman more than expected).
Fields of papers citing papers by Jeffrey A. Silverman
This network shows the impact of papers produced by Jeffrey A. Silverman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey A. Silverman. The network helps show where Jeffrey A. Silverman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jeffrey A. Silverman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2023 | 2 | |
| 3 | 2021 | 4 | |
| 4 | 2021 | 10 | |
| 5 | 2018 | 78 | |
| 6 | 2013 | 24 | |
| 7 | 2013 | 19 | |
| 8 | 2011 | 66 | |
| 9 | 2008 | 52 | |
| 10 | SNS-032 has potent antitumor activity in vivo against human leukemia and multiple myeloma xenografts | 2007 | 2 |
| 11 | SNS-595 potentiates the in vivo antitumor activity of carboplatin, cisplatin, and gemcitabine in solid tumor xenografts. | 2007 | 3 |
| 12 | 2003 | 30 | |
| 13 | 2000 | 22 | |
| 14 | 1999 | 219 | |
| 15 | 1999 | 367 | |
| 16 | 1998 | 151 | |
| 17 | 1994 | 39 | |
| 18 | 1994 | 7 | |
| 19 | 1993 | 72 | |
| 20 | 1992 | 60 |
About Jeffrey A. Silverman
Jeffrey A. Silverman is a scholar working on Oncology, Biochemistry and Genetics, having authored 93 papers that have together received 3.8k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (31 papers), Acute Lymphoblastic Leukemia research (15 papers), Pharmacological Effects and Toxicity Studies (12 papers), Cancer therapeutics and mechanisms (10 papers), Amino Acid Enzymes and Metabolism (9 papers), Chronic Lymphocytic Leukemia Research (6 papers), Childhood Cancer Survivors' Quality of Life (6 papers) and DNA Repair Mechanisms (5 papers). The work is most often cited by research in Oncology (2.0k citations), Pharmacology (619 citations) and Pharmaceutical Science (335 citations). Jeffrey A. Silverman has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Jay Dintaman, Steven R. Deitcher, Vincent J. Wacher, Leslie Z. Benet, Snorri S. Thorgeirsson, Yuanchao Zhang, Timothy W. Gant, Dieter Schrenk, Pamela A. Marino and Takashi Izumi. Their work appears in journals such as Nucleic Acids Research, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.